Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FLT3 mutant||acute myeloid leukemia||sensitive||Cytarabine + Daunorubicin + Midostaurin||Phase Ib/II||Actionable||In a Phase Ib clinical trial, Rydapt (midostaurin) treatment after Daunorubicin and Cytosar-U (cytarabine) induction resulted in complete remission in 92% (12/13) of acute myeloid leukemia patients carrying FLT3 mutations, although overall survival rate was similar to patients with wild-type FLT3 (PMID: 22627678).||22627678|
|FLT3 mutant||acute myeloid leukemia||sensitive||Cytarabine + Daunorubicin + Midostaurin||FDA approved - Has Companion Diagnostic||Actionable||In a Phase III trial that supported FDA approval, treatment with Rydapt (midostaurin), combined with Cytosar-U (cytarabine) and Daunorubicin, improved overall survival (HR=0.78, p=0.009) and event-free survival (HR=0.78, p=0.002) in patients with FLT3-mutant (ITD, D835X, and I836X mutations) acute myeloid leukemia compared to Cytosar-U (cytarabine) and Daunorubicin with placebo (PMID: 28644114; NCT00651261).||28644114 detail... detail...|
|PubMed Id||Reference Title||Details|
|(22627678)||Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia.||Full reference...|
|(28644114)||Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.||Full reference...|
|Rydapt (midostaurin) FDA Drug Label||Full reference...|